Zealand Pharma disappoints with diabetes drug in phase III

Crucial phase III trial with biotech firm Zealand Pharma's drug hope dasiglucagon did not live up to the hopes of the company and its investors.

Photo: Stine Bidstrup/Ritzau Scanpix

Zealand Pharma's first phase III trial with dasiglucagon for the treatment of congenital hyperinsulinism did not reach its primary endpoint, according to a statement issued by the firm. The company is, however, pleased with some of the partial results in the study and looks forward to developing drugs for the disease going forward.

The firm currently awaits results coming from a different phase III trial involving the rare disease, which entails low blood sugar levels caused by abnormally high insulin levels in the blood. In this trial, dasiglucagon is tested on infants with congenital hyperinsulinism.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs